Kadmon Holdings, Inc.:
Lead candidate is KD025, a ROCK2 inhibitor in in a pivotal clinical trial for chronic graft-versus-host disease (cGVHD); study outcome to be reported by YE 2019. A Ph2 trial of KD025 in systemic sclerosis is ongoing. Also developing KD033, an anti-PD-L1/IL-15 fusion protein; expected to enter the clinic in Q4 2019.
Phase l or ll
Autoimmune, Fibrosis, Oncology
100MM - 500MM
450 East 29th Street
New York, NY 10016
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by